Age-Related Eye Disease Study

Age-Related Eye Disease Study
Name	Age-Related Eye Disease Study
Date	1992–2005
Location	United States
Field	Ophthalmology
Sponsor	National Eye Institute; National Institutes of Health

Age-Related Eye Disease Study The Age-Related Eye Disease Study was a major randomized clinical trial coordinated by the National Eye Institute and funded by the National Institutes of Health to investigate progression and treatment of age-related macular degeneration and cataract in older adults. The trial enrolled volunteers across multiple sites in the United States and produced influential clinical recommendations, practice guidelines, and subsequent research programs involving multiple academic centers and collaborators. Key institutions and investigators included specialists affiliated with Johns Hopkins University, Massachusetts Eye and Ear, University of Wisconsin–Madison, and other leading research centers.

Overview

The trial aimed to evaluate risk factors, natural history, and preventive interventions for vision loss associated with age-related macular degeneration and cataract among older Americans. Recruitment and enrollment procedures referenced population cohorts and clinical networks at institutions such as Mayo Clinic, Harvard Medical School, University of California, San Francisco, and University of Pennsylvania. Study governance involved oversight from panels with representation from entities like the Food and Drug Administration and advisory input related to public health priorities discussed at meetings with participants from Centers for Disease Control and Prevention and advocacy groups including American Academy of Ophthalmology.

Study Design and Methods

The randomized, controlled design compared oral antioxidant and mineral supplementation against placebo and evaluated participants with stratification by baseline retinal findings using fundus photography and grading performed using standardized protocols developed by experts from Columbia University, Stanford University, and Yale University. The protocol specified inclusion and exclusion criteria informed by earlier cohort studies affiliated with University of Iowa Hospitals and Clinics and biostatistical plans reviewed by committees including members from Duke University and University of Michigan. Imaging modalities and outcome adjudication involved reading centers and masked examiners coordinated with laboratories at sites such as Washington University in St. Louis.

Major Findings and Outcomes

Primary outcomes demonstrated that a specific formulation of vitamins and minerals reduced the risk of progression to advanced age-related macular degeneration in selected high-risk groups, a result discussed at conferences featuring investigators from Brigham and Women's Hospital, Vanderbilt University Medical Center, and Northwestern University. Secondary analyses addressed effects on visual acuity, cataract surgery rates, and genotype–treatment interactions with contributions from teams at University of Texas Southwestern Medical Center and University of California, Los Angeles. Results informed clinical practice guidelines endorsed by professional societies including American Academy of Ophthalmology and were cited in systematic reviews by groups such as Cochrane collaborators.

Treatment Interventions and Supplements

The trial tested a combination supplement containing antioxidants and minerals formulated after consultation with pharmacology and nutrition experts at Columbia University Irving Medical Center and industry partners. The supplement components and dosages were debated at meetings attended by representatives from American Heart Association-affiliated nutrition panels and regulatory reviewers from the Food and Drug Administration. Trial protocols also documented lifestyle and risk-modification counseling drawing on epidemiologic evidence from cohorts involving investigators at University of Oxford and University of Cambridge.

Follow-up Studies and Long-term Results

Long-term follow-up extensions and ancillary studies assessed sustained benefits, safety signals, and genotype-specific responses; these investigations included analyses by teams at University of California, San Diego, Pennsylvania State University, and University College London. Data sharing and pooled analyses with other observational cohorts were coordinated with groups at Imperial College London and statistical collaborators from Harvard T.H. Chan School of Public Health, enabling meta-analyses and secondary publications addressing public health implications and cost-effectiveness communicated to stakeholders including Centers for Medicare & Medicaid Services.

Criticisms and Limitations

Critiques raised concerns about generalizability, dosing regimens, and applicability across diverse ancestral populations, with methodological discussions appearing in journals featuring authors from Johns Hopkins Bloomberg School of Public Health, University of Chicago, and Columbia Business School health economics units. Limitations also included reliance on fixed-dose formulations rather than individualized therapy, potential selection biases connected to recruitment sites such as academic medical centers, and evolving diagnostic technologies since the trial period that were later advanced at institutions like Massachusetts Institute of Technology and National Institutes of Health Clinical Center.

Category:Ophthalmology studies